SENSEX NIFTY
Divis Laboratories > Company History > Pharmaceuticals > Company History of Divis Laboratories - BSE: 532488, NSE: DIVISLAB
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Divis Laboratories
Divis Laboratories
BSE: 532488|NSE: DIVISLAB|ISIN: INE361B01024|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Nov 28, 16:15
1730.00
-2.8 (-0.16%)
VOLUME 5,586
LIVE
NSE
Nov 28, 16:15
1727.80
-8.8 (-0.51%)
VOLUME 124,153
Company History - Divis Laboratories
Milestones:
 1990 
 -Divis Research Center (DRC) established. 
 
 1991-1993 
 -DRC successfully develops several commercial processes for
 intermediates and bulk actives and supplies to manufacturing majors.
 
 
 1994
 -Divis Research Center changes its name to Divis Laboratories Limited
 to reflect its growing area of operations and its plans to enter the
 manufacturing sector in the following year. 
 
 1995
 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts
 operations. 
 
 1997 
 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002
 compliant. 
 
 1999
 -European Directorate gives a “Certificate of Suitability” (CoS) for
 Naproxen produced at Divis Laboratories. 
 
 2000
 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K
 awards Divis the ISO 9001 Certification SGS International AG of
 Switzerland awards Divis the ISO-14001 Certification (for its
 efficient Environment Management Systems). 
 
 2001
 -BVQI of London awards Divis the OHSAS-18001 Certification (for its
 Occupational Health and Safety Management Systems). 
 
 2002
 -Divis commences the setting up of its 2nd Manufacturing Facility
 (Unit-2) at Chippada near Visakhapatnam.
 
 2003
 -Divis opens a new research center christened ‘DRC-Vizag’ for
 fundamental research in selected niche business core segments.
 
 -Went for IPO and listed on stock exchanges BSE, NSE and HSE. 
 
 -Divi's Laboratorie receives Certificate of Substantiability from the
 council of Europe
 
 -Appointed Mr A Narendra as Company Secretary & Compliance Officer of
 the company (in place of outgoing Company Secretary Mr P Sudarshan)
 who has joined the organization.
 
 2004
 
 - Divi'S Laboratories Limited has informed that the manufacturing
 facility of Divi's Labs at Choutuppal near Hyderabad was successfully
 inspected by US-FDA in May 2004.
 
 -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 
 
 2006
 
 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE),
 Hyderabad with effect from March 29, 2006.
 
 -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 
 
 2007
 
 - The Company has splits its face value from Rs10/- to Rs2/-.
 
 2008
 -Third US-FDA inspection for Choutuppal(Unit-1).
 
 2009
 
 - Certified and Awarded for Best Green Belt Development
 
 - SURAKSHA PURASKAR for the year 2008
 
 - ISO 14001: 2004 (Re-Certification) Environment Management System
 
 -Divi's Laboratories has given the Bonus in the Ratio of 1:1
 
 2010
 
 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam.
 
 - The Company has recommended a dividend of 300% i.e. Rs. 6/- per
 equity share of Rs. 2/- face value for the year ended March 31,
 2010.
 
 2011
 
 - Divi’s Laboratories surged 3.5 per cent in early morning
 trade on Bombay Stock Exchange on November 2, 2011, after the
 announcement of healthy growth in Q2 numbers on November 1, 2011,
 after trading hours.
 
 - Shares of the company after opening higher at Rs 765 from previous
 close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE,
 reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was
 trading at Rs 772.85 on Bombay Stock Exchange.
 
 2012
 
 - Divis Laboratories Ltd has informed BSE that the Board of Directors
 through Circular resolution dated March 07, 2012 has decided to seek
 shareholders approval by postal ballot for Re-appointment and
 revision in remuneration of Mr. Madhusudana Rao Divi as
 Director-Projects of the Company.
 
 - The Company Re-appointment and revision in remuneration of Mr.
 Kiran S. Divi Director & President- Operations of the Company.
 
 -  Enhancement of remuneration of Dr. Murali K. Divi, Chairman &
 Managing Director of the Company.
 
 - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director
 of the Company.
Source : Dion Global Solutions Limited
Quick Links for Divis Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.